Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company focuses on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company specializes in the treatment of induced dysfunction in parkinson"s disease, schizophrenia, neuropathic pain, and glaucoma.
Website: acadia-pharm.com


  • Bad financial results growth rate -38.7% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (62.8%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 1.8% (LTM)
  • Share price is 49.0% higher than minimum and 37.2% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (25.3x vs 30.0x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.9 mln (-0.025% of cap.)

Key Financials (Download financials)

Ticker: ACAD
Share price, USD:  (+0.6%)21.01
year average price 24.63  


year start price 21.77 2025-06-04

min close price 20.06 2025-10-10

max close price 28.06 2025-12-22

current price 20.89 2026-06-03
Common stocks: 169 335 000

Dividend Yield:  0.0%
FCF Yield LTM: 1.8%
EV / LTM EBITDA: 25.3x
EV / EBITDA annualized: 32.8x
Last revenue growth (y/y):  +9.2%
Last growth of EBITDA (y/y):  -86.6%
Historical revenue growth:  +29.8%
Historical growth of EBITDA:  +95.8%
EV / Sales: 2.6x
Margin (EBITDA LTM / Revenue): 10.2%

Target EV / EBITDA (hist percentile): 30.0x
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 3 537
Net Debt ($m): -779
EV (Enterprise Value): 2 758
EBITDA LTM (млн $): 109
EV / LTM EBITDA: 25.3x
Price to Book: 3.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-03zacks.com

5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates

2026-02-02zacks.com

Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again

2025-12-04seekingalpha.com

Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality

2025-12-03fool.com

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?

2025-11-28zacks.com

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock

2025-11-12zacks.com

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term

2025-11-10seekingalpha.com

ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript

2025-11-06seekingalpha.com

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript

2025-10-28zacks.com

Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect?

2025-10-22businesswire.com

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-07 2024-05-09 2023-11-03 2023-08-03 2023-05-08 2022-11-03
acceptedDate 2025-11-05 18:47:23 2025-08-06 17:53:50 2025-02-27 17:26:09 2024-11-06 17:41:01 2024-08-06 19:48:56 2024-05-08 19:13:29 2023-12-30 19:00:00 2023-11-02 18:33:43 2023-08-02 19:29:22 2023-05-08 17:29:46 2023-02-27 18:38:37 2022-11-02 20:29:53 2022-03-01 06:03:15 2021-02-24 21:54:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 279M 265M 958M 250M 242M 206M 726M 212M 165M 118M 517M 131M 484M 442M
costOfRevenue 22M 21M 82M 19M 18M 23M 46M 15M 7M 2M 10M 2M 19M 21M
grossProfit 257M 244M 876M 232M 224M 183M 681M 197M 158M 117M 507M 129M 465M 421M
grossProfitRatio 0.922 0.922 0.925 0.925 0.888 0.931 0.955 0.986 0.984
researchAndDevelopmentExpenses 88M 78M 303M 67M 76M 60M 352M 157M 59M 69M 362M 81M 239M 319M
generalAndAdministrativeExpenses 0 0 0 0 0 0 393M 0 96M 0 0 0 396M 389M
sellingAndMarketingExpenses 0 0 0 0 0 0 9M 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 133M 134M 488M 133M 117M 108M 402M 98M 96M 101M 369M 78M 396M 389M
otherExpenses 0 0 -147M 0 386 000 286 000 0 2M -1M 5M 0 0 0 0
operatingExpenses 221M 211M 645M 200M 193M 168M 754M 255M 155M 170M 731M 159M 635M 708M
costAndExpenses 243M 232M 727M 219M 212M 191M 800M 269M 162M 172M 741M 162M 655M 728M
interestIncome 8M 7M 25M 7M 6M 6M 17M 4M 5M 4M 7M 2M 591 000 7M
interestExpense 0 0 0 0 0 0 0 0 0 -9M 0 2M 0 0
depreciationAndAmortization 3M 3M 16M 0 3M 6M 6M 2M 2M 426 000 2M 0 3M 3M
ebitda 48M 35M 100M 32M 33M 21M -68M -58M 3M -54M -222M -31M -167M -284M
ebitdaratio 0.171 0.133 0.126 0.136 0.101 -0.273 0.018 -0.452 -0.236
operatingIncome 36M 32M 231M 32M 30M 15M -73M -58M 3M -54M -224M -31M -170M -287M
operatingIncomeRatio 0.128 0.122 0.126 0.126 0.074 -0.273 0.018 -0.452 -0.236
totalOtherIncomeExpensesNet 9M 8M 27M 7M 7M 286 000 22M 2M -1M 9M 10M 4M 3M 6M
incomeBeforeTax 45M 40M 258M 39M 37M 21M -51M -52M 6M -45M -213M -26M -168M -281M
incomeBeforeTaxRatio 0.16 0.152 0.155 0.154 0.102 -0.246 0.038 -0.379 -0.202
incomeTaxExpense -27M 14M 32M 6M 4M 4M 10M 13M 5M -2M 3M 768 000 351 000 611 000
netIncome 72M 27M 226M 33M 33M 17M -61M -65M 1M -43M -216M -27M -168M -282M
netIncomeRatio 0.258 0.101 0.131 0.138 0.08 -0.308 0.007 -0.363 -0.208
eps 0.43 0.16 1.37 0.2 0.2 0.1 -0.37 -0.4 0.01 -0.27 -1.34 -0.17 -1.05 -1.79
epsdiluted 0.42 0.16 0.2 0.2 0.1 -0.4 0.01 -0.27 -0.17
weightedAverageShsOut 169M 168M 166M 166M 166M 165M 164M 164M 165M 162M 162M 162M 160M 157M
weightedAverageShsOutDil 171M 169M 166M 166M 166M 167M 164M 164M 165M 162M 162M 162M 160M 157M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2023-12-31 2023-02-28 2022-03-01 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 25M 17M 7M 591 000 7M
ebit 84M -73M -224M -170M -287M
nonOperatingIncomeExcludingInterest 147M 0 0 0 0
netIncomeFromContinuingOperations 226M -61M -216M -168M -282M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 226M -61M -216M -168M -282M
epsDiluted 1.36 -0.37 -1.34 -1.05 -1.79

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-07 2024-05-09 2023-11-03 2023-08-03 2023-05-08 2022-11-03
acceptedDate 2025-11-05 18:47:23 2025-08-06 17:53:50 2025-02-27 17:26:09 2024-11-06 17:41:01 2024-08-06 19:48:56 2024-05-08 19:13:29 2024-02-27 16:01:19 2023-11-02 18:33:43 2023-08-02 19:29:22 2023-05-08 17:29:46 2023-02-27 16:38:37 2022-11-02 20:29:53 2022-03-01 06:03:15 2021-02-24 21:54:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 258M 254M 320M 155M 177M 205M 189M 98M 108M 291M 115M 155M 147M 326M
shortTermInvestments 589M 508M 436M 410M 324M 266M 250M 248M 267M 112M 302M 282M 373M 306M
cashAndShortTermInvestments 847M 762M 756M 565M 501M 471M 439M 346M 375M 403M 417M 437M 521M 632M
netReceivables 139M 120M 105M 98M 110M 100M 102M 95M 84M 70M 63M 56M 65M 50M
inventory 29M 26M 22M 61M 72M 62M 36M 21M 9M 6M 7M 6M 8M 10M
otherCurrentAssets 61M 53M 0 64M 46M 48M 0 40M 26M 28M 0 23M 0 0
totalCurrentAssets 1 076M 961M 938M 788M 729M 675M 616M 499M 493M 503M 508M 522M 618M 718M
propertyPlantEquipmentNet 53M 55M 51M 48M 57M 59M 56M 56M 58M 60M 62M 63M 66M 56M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 112M 114M 120M 106M 108M 110M 65M 67M 68M 70M 0 0 0 1M
goodwillAndIntangibleAssets 112M 114M 120M 106M 108M 110M 65M 67M 68M 70M 0 0 0 1M
longTermInvestments 9M 9M 0 0 6M 6M 6M 6M 8M 0 13M 0 0 7M
taxAssets 0 0 0 0 0 -6M 0 -6M -8M 0 0 0 0 0
otherNonCurrentAssets 80M 87M 79M 35M 15M 11M 5M 11M 24M 23M 5M 18M 16M 378 000
totalNonCurrentAssets 254M 265M 249M 189M 185M 180M 133M 133M 150M 152M 80M 81M 82M 65M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 331M 1 226M 1 188M 977M 914M 855M 749M 633M 643M 655M 588M 602M 700M 783M
accountPayables 22M 20M 16M 19M 20M 19M 18M 12M 19M 17M 13M 10M 7M 8M
shortTermDebt 12M 12M 0 9M 10M 10M 9M 9M 9M 9M 0 9M 0 5M
taxPayables 0 0 12M 0 8M 8M 2M 8M 0 0 377 000 0 0 0
deferredRevenue 0 0 0 0 8M -10M 0 -9M -9M 0 0 0 0 0
otherCurrentLiabilities 323M 298M 37M 316M 299M 311M 92M 197M 169M 198M 50M 97M 26M 52M
totalCurrentLiabilities 357M 330M 395M 344M 338M 331M 254M 210M 188M 224M 126M 117M 96M 106M
longTermDebt 43M 45M 0 40M 94M 49M 0 48M 50M 51M 0 54M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 14M 29M 18M 15M -35M 11M 15M 13M 9M 5M 9M 41M 7M 5M
totalNonCurrentLiabilities 57M 73M 60M 56M 60M 60M 63M 61M 59M 57M 62M 60M 63M 50M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 43M 45M 52M 9M 58M 60M 48M 48M 50M 51M 62M 54M 64M 44M
totalLiabilities 413M 403M 455M 400M 397M 391M 317M 270M 247M 281M 187M 177M 159M 156M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 16 000 16 000 16 000 16 000 16 000 16 000 16 000 16 000 16 000 16 000 16 000 16 000 16 000 16 000
retainedEarnings -2 087M -2 159M -2 204M -2 348M -2 381M -2 414M -2 431M -2 477M -2 411M -2 413M -2 370M -2 328M -2 154M -1 986M
accumulatedOtherComprehensiveIncomeLoss 989 000 406 000 292 000 858 000 -339 000 -229 000 24 000 -319 000 -535 000 -220 000 -975 000 -1M -192 000 36 000
othertotalStockholdersEquity 3 003M 2 981M 2 924M 2 898M 2 879M 2 839M 2 808M 2 787M 2 755M
totalStockholdersEquity 917M 822M 733M 577M 517M 464M 432M 362M 396M 374M 400M 426M 541M 627M
totalEquity 917M 822M 733M 577M 517M 464M 432M 362M 396M 374M 400M 426M 541M 627M
totalLiabilitiesAndStockholdersEquity 1 331M 1 226M 977M 914M 855M 633M 643M 655M 602M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 331M 1 226M 1 188M 977M 914M 855M 749M 633M 643M 655M 588M 602M 700M 783M
totalInvestments 598M 518M 436M 410M 330M 266M 256M 248M 267M 112M 315M 282M 373M 313M
totalDebt 55M 56M 52M 49M 58M 60M 57M 48M 50M 51M 62M 54M 64M 50M
netDebt -203M -197M -268M -106M -119M -145M -131M -50M -58M -239M -53M -101M -83M -276M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-02-28 2022-03-01 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 99M 98M 62M 64M 48M
otherReceivables 6M 4M 885 000 978 000 2M
prepaids 56M 39M 21M 24M 26M
totalPayables 28M 19M 13M 7M 8M
otherPayables 12M 2M 0 0 0
accruedExpenses 320M 133M 54M 55M 40M
capitalLeaseObligationsCurrent 10M 0 9M 8M 0
capitalLeaseObligationsNonCurrent 42M 48M 53M 56M 44M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 937M 2 863M 2 771M 2 695M 2 613M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD ACAD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-07 2024-05-09 2023-11-03 2023-08-03 2023-05-08 2022-11-03
acceptedDate 2025-11-05 18:47:23 2025-08-06 17:53:50 2025-02-27 17:26:09 2024-11-06 17:41:01 2024-08-06 19:48:56 2024-05-08 19:13:29 2024-02-27 16:01:19 2023-11-02 18:33:43 2023-08-02 19:29:22 2023-05-08 17:29:46 2023-02-27 16:38:37 2022-11-02 20:29:53 2022-03-01 06:03:15 2021-02-24 21:54:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 72M 27M 226M 33M 33M 17M -61M -65M 1M -43M -216M -27M -168M -282M
depreciationAndAmortization 3M -1M 16M -5M 3M 6M 6M 2M 2M 426 000 2M 506 000 3M 3M
deferredIncomeTax 0 0 0 0 0 0 0 -50M 16M 0 0 0 0 3M
stockBasedCompensation 13M 14M 67M 26M 16M 15M 66M 19M 15M 15M 68M 18M 64M 84M
changeInWorkingCapital -13M 22M 4M 31M -25M -6M 18M -11M -10M 17M 38M 11M -25M 11M
accountsReceivables -20M -6M -2M 7M -10M 4M -39M -11M -16M -4M 2M 12M -16M -12M
inventory 1M -4M -50M -1M -27M -17M -29M -11M -3M 481 000 2M 640 000 -4M -3M
accountsPayables 2M 2M -1M -801 000 550 000 2M 5M -7M 1M 5M 6M -2M -2M 1M
otherWorkingCapital 4M 30M 57M 26M 12M 7M 81M 18M 8M 15M 27M -31 000 -3M 26M
otherNonCashItems -1M 3M -156M -22M 56M 37M -12M 47M -16M -7M -6M -3M 75 000 44M
netCashProvidedByOperatingActivities 74M 64M 158M 63M 25M 29M 17M -59M 8M -18M -114M -727 000 -126M -136M
investmentsInPropertyPlantAndEquipment -388 000 99M -523 000 -70 000 0 0 -40M -50 000 -40M 0 0 0 -1M -8M
acquisitionsNet 0 0 0 0 0 0 -32M 50 000 40M 0 0 0 70M -200M
purchasesOfInvestments -205M -174M -505M -151M -138M -80M -370M -37M -162M -67M -363M -144M -493M -340M
salesMaturitiesOfInvestments 126M 131M 329M 69M 82M 66M 442M 71M 8M 259M 436M 160M 423M 540M
otherInvestingActivites 0 -99M 0 -56M -14M -50 000 -40M 0 0
netCashUsedForInvestingActivites -79M -43M -82M -56M -14M 34M -194M 193M 15M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 9M 16M 268 000 4M 1M 13M 5M 1M 287 000
commonStockRepurchased 0 0 0 0 0 0 0 0 3M 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 0 0 1M 13M -3M 0 0
netCashUsedProvidedByFinancingActivities 9M 16M 268 000 4M 1M 13M 5M 1M 287 000
effectOfForexChangesOnCash 0 24 000 -94 000 -42 000 3000 5000 -18 000 -4000 200M -2000 6000 8000 7000 -8000
netChangeInCash 4M 37M 134M -13M -28M 16M 74M -12M -181M 176M -33M 15M -179M 137M
cashAtEndOfPeriod 267M 263M 328M 164M 177M 211M 189M 104M 116M 297M 121M 161M 153M 332M
cashAtBeginningOfPeriod 263M 226M 194M 177M 205M 194M 115M 116M 297M 121M 153M 146M 332M 194M
operatingCashFlow 74M 64M 158M 63M 25M 29M 17M -59M 8M -18M -114M -727 000 -126M -136M
capitalExpenditure -388 000 99M -523 000 -70 000 0 0 -40M -50 000 -40M 0 0 0 -1M -8M
freeCashFlow 74M 162M 157M 63M 25M 29M -23M -59M -32M -18M -114M -727 000 -127M -144M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-28 2023-02-28 2022-03-01 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 147M 32M 0 -70M 200M
netCashProvidedByInvestingActivities -31M 32M 73M -71M 193M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 7M 25M 8M 18M 81M
netCommonStockIssuance 7M 25M 8M 18M 81M
commonStockIssuance 7M 25M 8M 18M 81M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 0 0
netCashProvidedByFinancingActivities 7M 25M 8M 18M 81M
incomeTaxesPaid 20M 6M 2M 1M 1M
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-03 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-02-27 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-06 20:05 ET
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
2026-04-30 20:05 ET
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
2026-04-28 20:05 ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2026-04-17 ET
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
2026-04-15 ET
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
2026-04-07 ET
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
2026-03-12 ET
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
2026-03-03 ET
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
2026-03-02 ET
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
2026-02-25 ET
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
2026-02-23 ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2026-02-04 21:05 ET
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
2026-02-02 ET
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
2026-01-13 ET
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
2025-12-18 ET
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
2025-12-12 ET
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
2025-11-20 ET
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
2025-11-05 ET
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
2025-10-28 ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2025-10-15 ET
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
2025-10-02 ET
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
2025-09-24 ET
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
2025-09-12 ET
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
2025-08-26 ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2025-08-25 ET
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
2025-08-05 ET
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
2025-08-04 ET
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
2025-07-23 ET
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
2025-06-25 ET
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
2025-06-09 ET
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
2025-06-05 ET
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
2025-05-29 ET
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
2025-05-27 ET
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
2025-05-20 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-16 ET
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
2025-05-07 ET
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
2025-05-05 ET
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
2025-04-23 ET
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
2025-04-11 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-14 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-13 ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2025-03-05 ET
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
2025-03-03 ET
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
2025-02-27 ET
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
2025-02-26 ET
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
2025-02-14 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-12 ET
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
2025-01-17 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-14 ET
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
2025-01-14 ET
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
2024-12-30 ET
Acadia Pharmaceuticals Set to Join S&P SmallCap 600
2024-12-19 ET
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
2024-12-16 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-12-11 ET
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
2024-12-09 ET
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
2024-11-26 ET
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
2024-11-21 ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2024-11-15 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-07 12:00 ET
Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome
2024-11-06 21:05 ET
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
2024-11-05 21:05 ET
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
2024-10-16 20:07 ET
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
2024-10-08 20:05 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-26 20:05 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-23 20:15 ET
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
2024-08-28 20:05 ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2024-08-14 12:04 ET
Ryan Reynolds Announces More to Parkinson’s® Campaign
2024-08-07 20:30 ET
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
2024-08-06 20:05 ET
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
2024-07-24 20:05 ET
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
2024-07-18 13:04 ET
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
2024-06-18 13:04 ET
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
2024-05-17 20:05 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-15 13:05 ET
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
2024-05-09 20:58 ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2024-05-08 20:05 ET
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
2024-04-29 20:16 ET
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
2024-04-24 20:05 ET
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
2024-04-22 13:04 ET
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
2024-04-19 20:05 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-17 20:05 ET
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
2024-04-02 20:05 ET
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
2024-04-01 20:05 ET
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-03-15 20:05 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-13 20:05 ET
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
2024-03-11 20:05 ET
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
2024-02-29 14:05 ET
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
2024-02-27 21:05 ET
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
2024-02-21 21:05 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-13 21:05 ET
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2024-01-31 01:48 ET
Acadia Announces Additions to Executive Team
2024-01-19 21:05 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-18 21:05 ET
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
2023-12-21 21:05 ET
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
2023-12-18 21:05 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-14 02:24 ET
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
2023-12-13 18:41 ET
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
2023-11-30 14:05 ET
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
2023-11-27 14:05 ET
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
2023-11-21 22:00 ET
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
2023-11-14 21:12 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-02 20:05 ET
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
2023-10-31 20:05 ET
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
2023-10-23 13:05 ET
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
2023-10-19 20:05 ET
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
2023-10-18 21:00 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-22 22:23 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-19 20:05 ET
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
2023-08-30 20:05 ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2023-08-14 20:05 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-02 20:05 ET
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
2023-08-01 23:30 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-07-24 20:05 ET
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
2023-07-19 20:04 ET
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
2023-07-13 20:05 ET
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
2023-06-26 21:00 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-13 20:05 ET
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
2023-06-08 15:10 ET
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
2023-06-01 13:04 ET
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
2023-05-08 20:05 ET
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
2023-05-05 20:04 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-02 13:04 ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
2023-04-25 13:04 ET
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
2023-04-20 13:04 ET
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
2023-04-17 13:04 ET
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
2023-04-11 13:04 ET
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
2023-03-20 18:00 ET
Headline
2023-03-11 02:45 ET
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
2023-02-27 21:05 ET
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
2023-02-14 21:05 ET
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
2023-02-13 21:15 ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-09 14:00 ET
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
2023-01-03 14:00 ET
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
2022-12-21 21:05 ET
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
2022-11-08 21:05 ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2022-11-02 20:05 ET
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
2022-10-27 20:05 ET
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
2022-10-20 20:05 ET
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
2022-10-13 11:30 ET
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
2022-10-04 11:30 ET
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
2022-09-12 11:30 ET
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
2022-09-01 13:03 ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
2022-08-08 20:05 ET
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
2022-08-05 03:05 ET
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
2022-07-25 20:05 ET
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
2022-07-18 20:07 ET
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
2022-06-18 00:00 ET
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
2022-06-17 11:05 ET
Acadia Pharmaceuticals Stock Trading Halted Today
2022-05-04 20:05 ET
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
2022-05-03 20:05 ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
2022-05-02 20:05 ET
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
2022-04-21 13:00 ET
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
2022-04-18 20:05 ET
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
2022-03-22 13:00 ET
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
2022-03-10 21:05 ET
Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022
2022-03-09 13:30 ET
Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
2022-03-03 14:00 ET
Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
2022-02-28 21:05 ET
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-16 14:00 ET
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
2022-02-14 14:00 ET
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
2022-02-11 14:00 ET
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
2022-01-10 12:00 ET
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
2021-12-22 14:00 ET
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
2021-12-20 21:05 ET
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
2021-12-14 14:00 ET
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
2021-12-06 21:05 ET
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
2021-12-01 14:00 ET
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
2021-11-16 14:00 ET
Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
2021-11-08 21:05 ET
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
2021-11-02 13:00 ET
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
2021-11-01 20:05 ET
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
2021-10-27 13:00 ET
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
2021-10-25 13:00 ET
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
2021-09-02 13:00 ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
2021-09-01 20:05 ET
Acadia Pharmaceuticals Announces Executive Leadership Change
2021-08-05 20:05 ET
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021
2021-08-04 20:05 ET
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
2021-07-21 21:05 ET
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
2021-07-21 13:00 ET
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
2021-07-14 13:00 ET
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
2021-06-03 13:00 ET
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders
2021-05-26 13:00 ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
2021-05-05 20:10 ET
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
2021-05-04 13:00 ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
2021-04-21 13:00 ET
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
2021-04-05 10:30 ET
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
2021-03-08 21:05 ET
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
2021-02-24 21:05 ET
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-19 14:00 ET
Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
2021-02-18 14:00 ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
2021-02-10 14:00 ET
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
2021-01-27 21:05 ET
Acadia Pharmaceuticals Announces Commercial Leadership Change
2020-12-22 14:00 ET
Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
2020-11-10 14:00 ET
Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
2020-11-04 21:05 ET
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
2020-10-26 13:00 ET
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
2020-10-21 20:05 ET
Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
2020-10-14 20:05 ET
The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”
2020-10-01 13:00 ET
Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
2020-09-02 13:00 ET
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
2020-08-31 13:00 ET
ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
2020-08-25 13:00 ET
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
2020-08-12 13:00 ET
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
2020-08-05 20:05 ET
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
2020-07-29 13:00 ET
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
2020-07-22 20:05 ET
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
2020-07-20 20:03 ET
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
2020-07-20 20:02 ET
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
2020-06-15 13:00 ET
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
2020-06-02 13:00 ET
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
2020-05-28 13:00 ET
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
2020-05-26 13:00 ET
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
2020-05-21 13:00 ET
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
2020-05-07 20:06 ET
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
2020-05-07 20:05 ET
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
2020-05-05 20:05 ET
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
2020-04-15 20:05 ET
ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
2020-03-03 22:50 ET
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
2020-02-26 21:05 ET
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-24 14:00 ET
ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
2020-02-12 14:00 ET
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
2020-01-07 14:00 ET
ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
2019-12-18 21:05 ET
ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer
2019-12-05 01:45 ET
ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
2019-11-25 21:03 ET
ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
2019-11-11 14:00 ET
ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019
2019-11-04 14:00 ET
ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
2019-10-30 20:15 ET
ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
2019-10-30 20:05 ET
ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
2019-10-16 13:00 ET
ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019
2019-10-07 13:00 ET
ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress
2019-10-03 20:55 ET
ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting
2019-09-25 20:05 ET
ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
2019-09-24 20:05 ET
ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder
2019-09-23 13:00 ET
ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
2019-09-20 20:05 ET
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2019-09-19 13:00 ET
ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings
2019-09-18 03:00 ET
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
2019-09-17 20:02 ET
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
2019-09-09 13:31 ET
Thinking about buying stock in Acadia Pharmaceuticals, Aurora Cannabis, Bank of America, SINTX Technologies, or AT&T?
2019-09-09 10:30 ET
ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
2019-07-31 20:05 ET
ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
2019-06-25 12:50 ET
New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
2019-04-17 13:00 ET
ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
2019-04-11 13:00 ET
ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
2019-04-02 13:00 ET
ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019

SEC forms

Show financial reports only

SEC form 8
2026-02-25 16:20 ET
ACADIA Pharmaceuticals reported for 2025 q4
SEC form 8
2026-02-25 16:20 ET
ACADIA Pharmaceuticals published news for 2025 q4
SEC form 8
2025-11-05 16:13 ET
ACADIA Pharmaceuticals reported for 2025 q3
SEC form 8
2025-11-05 16:13 ET
ACADIA Pharmaceuticals published news for 2025 q3
SEC form 10
2025-08-06 21:53 ET
ACADIA Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-06 20:18 ET
ACADIA Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-06 20:18 ET
ACADIA Pharmaceuticals published news for 2025 q2
SEC form 10
2025-05-08 01:15 ET
ACADIA Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
ACADIA Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-07 20:13 ET
ACADIA Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-07 20:13 ET
ACADIA Pharmaceuticals reported for 2025 q1
SEC form 8
2025-04-16 20:15 ET
ACADIA Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-16 20:15 ET
ACADIA Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-27 22:26 ET
ACADIA Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
ACADIA Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
ACADIA Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
ACADIA Pharmaceuticals reported for 2024 q4
SEC form 10
2024-11-06 17:41 ET
ACADIA Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-06 16:14 ET
ACADIA Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-06 16:14 ET
ACADIA Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-07 00:00 ET
ACADIA Pharmaceuticals published news for 2024 q2
SEC form 10
2024-08-06 19:48 ET
ACADIA Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-06 16:13 ET
ACADIA Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-06 16:13 ET
ACADIA Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
ACADIA Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-08 00:00 ET
ACADIA Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
ACADIA Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-28 00:00 ET
ACADIA Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-27 18:01 ET
ACADIA Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-27 16:16 ET
ACADIA Pharmaceuticals reported for 2023 q4
SEC form 8
2024-02-27 16:16 ET
ACADIA Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-03 00:00 ET
ACADIA Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-02 18:33 ET
ACADIA Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-02 16:21 ET
ACADIA Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-03 00:00 ET
ACADIA Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-02 19:29 ET
ACADIA Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-02 16:23 ET
ACADIA Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-02 00:00 ET
ACADIA Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-18 16:01 ET
ACADIA Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-02 16:10 ET
ACADIA Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
ACADIA Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
ACADIA Pharmaceuticals published news for 2023 q1
SEC form 8
2023-02-28 00:00 ET
ACADIA Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
ACADIA Pharmaceuticals reported for 2022 q4
SEC form 10
2022-11-03 00:00 ET
ACADIA Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
ACADIA Pharmaceuticals reported for 2022 q3
SEC form 10
2022-08-09 00:00 ET
ACADIA Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-08 00:00 ET
ACADIA Pharmaceuticals reported for 2022 q2
SEC form 10
2022-05-05 00:00 ET
ACADIA Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
ACADIA Pharmaceuticals reported for 2022 q1
SEC form 10
2022-03-01 00:00 ET
ACADIA Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
ACADIA Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-09 00:00 ET
ACADIA Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
ACADIA Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-05 00:00 ET
ACADIA Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
ACADIA Pharmaceuticals published news for 2021 q2
SEC form 10
2021-05-06 00:00 ET
ACADIA Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
ACADIA Pharmaceuticals published news for 2021 q1